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Objective: The purpose of this study was to determine the implication of idiopathic pulmonary fibrosis on the
surgical treatment for primary lung cancer.
Methods: Between January 1994 and June 2006, 870 patients with primary lung cancer were surgically treated.
Fifty-six (6.4%) of 870 patients had complications with idiopathic pulmonary fibrosis, and their data were retro-
spectively reviewed. There were 50 men and 6 women with an average age of 68 years. The incidence of squa-
mous cell carcinoma was 28 (50.0%). Surgical procedures consisted of 7 wedge resections of the lung,
5 segmentectomies, 43 lobectomies, and 1 bilobectomy.
Results: Surgery-related hospital mortality was higher in patients with idiopathic pulmonary fibrosis than in pa-
tients without (7.1% vs 1.9%; P¼ .030). Four (7.1%) of these 56 patients had acute postoperative exacerbation
of pulmonary fibrosis and died because of this complication. No factors such as pulmonary function, serologic
data, operative data, and histopathologic data were considered predictive risk factors for the acute exacerbation.
The postoperative 5-year survival for pathologic stage I lung cancer was 61.6% for patients with idiopathic pul-
monary fibrosis and 83.0% for patients without (P¼ .019). The causes of late death were the recurrence of cancer
or respiratory failure owing to idiopathic pulmonary fibrosis.
Conclusions: Although idiopathic pulmonary fibrosis causes high mortality after pulmonary resection for lung
cancer and poor long-term survival, long-term survival is possible in patients with these two fatal diseases. There-
fore, in selected patients, idiopathic pulmonary fibrosis may not be a contraindication to pulmonary resection for
stage I lung cancer.G
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Idiopathic pulmonary fibrosis (IPF) is known to be concom-
itant with primary lung cancer (PLC) and sometimes causes
catastrophic results after pulmonary resection. Acute post-
operative exacerbation of IPF is one of the fatal complica-
tions after lung resection. Mortality after the occurrence of
this complication is very high (80%–100%).1,2Although
some efforts have been made to establish the cause of acute
postoperative exacerbation in order to prevent it,3,4 the influ-
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tive mortality, morbidity, and long-term survival after
pulmonary resection for PLC has not been well studied.
Hence, this study examines the implication of IPF on surgi-
cal results of pulmonary resection for PLC.
PATIENTS AND METHODS
Patients
Between January 1994 and June 2006, 870 patients with PLC were sur-
gically treated in our institute. Sixty-eight of 870 patients had complica-
tions with diffuse parenchymal lung disease. Ten patients with diffuse
parenchymal lung disease and concomitant collagen diseases (rheumatoid
arthritis in 3, Sjo¨gren syndrome in 3, mixed collagen tissue diseases in 2,
and progressive systemic sclerosis in 2) and 2 patients with nonspecific
interstitial pneumonia were excluded from this study because these types
of diffuse parenchymal lung diseases have different outcomes from IPF.
Therefore, the inclusion criteria of this study were surgically treated pa-
tients with PLC concomitant with IPF (n ¼ 56) and patients with PLC
without diffuse parenchymal lung disease (n ¼ 802). The medical records
of 858 consecutive patients with PLC were retrospectively reviewed. Data
acquisition and analysis were approved by our institutional review board.
The records contained preoperative patient characteristics, disease status,
operative procedures, pathologic diagnosis, and follow-up data. Idiopathic
interstitial pneumonia was preoperatively diagnosed in all patients with
IPF. This included 45 confident chest computed tomography diagnoses
of IPF with consistent clinical features: fine crackles (resembling the
sound of hook-and-loop fasteners) on chest auscultation and abnormali-
ties, such as peripheral reticular opacity or honeycombing, on preoperative
chest computed tomography. Furthermore, after surgery, idiopathic pul-
monary fibrosis/usual interstitial pneumonia (IPF/UIP) was definitively di-
agnosed in all patients with IPF by histopathologic assessment of the
resected lung (architectural destruction, fibrosis often with honeycombing,ardiovascular Surgery c Volume 136, Number 5 1357




ARDS ¼ acute respiratory distress syndrome
FEV1.0 ¼ forced expiratory volume in one second
IPF ¼ idiopathic pulmonary fibrosis
OLV ¼ one-lung ventilation
PF ¼ pulmonary fibrosis
PLC ¼ primary lung cancer
UIP ¼ usual interstitial pneumonia
VC ¼ vital capacity
scattered fibroblastic foci, patchy distribution, and involvement of the pe-
riphery of the acinus or lobule). The incidence of male sex, squamous cell
carcinoma, wedge resection, and lower lobe tumor was higher in patients
with IPF than in patients without. Furthermore, the percentage of diffusion
capacity of the lung for carbon monoxide was higher in patients with IPF
than in patients without. Patients with IPF underwent 7 wedge resections
of the lung, 5 segmentectomies, 43 lobectomies, and 1 bilobectomy as sur-
gical treatment for lung cancer. Pathologic stages were I in 28, II in 5, III in
14, and IV in 3 patients (Table 1).
Inclusion Criteria for Pulmonary Resection
Lobectomy was selected when the postoperative predictive forced expi-
ratory volume in 1 second (FEV1.0) was 1.2 L or greater. However, segmen-
tectomy was selected when lobectomy could lead to a postoperative
predictive FEV1.0 of less than 1.2 L. Furthermore, segmentectomy was ag-
gressively selected also when the greatest diameter for resection was 20 mm
or less, even when the postoperative predictive FEV1.0 was 1.2 L or more.
Definition of Each Disorder
In this study, we used the criteria of acute exacerbation of IPF as de-
scribed previously by Yoshimura and associates,5 namely, (1) intensified
dyspnea, (2) increase in the interstitial shadow on chest radiograph, (3) in-
crease in fine crackles on auscultation, (4) elevation of serum lactate dehy-
drogenase, and (5) decrease in arterial oxygen tension of more than 10 mm
Hg under similar condition. Furthermore, we added the elevation of serum
surfactant protein-D or sialylated carbohydrate antigen KL-6 to criterion 4.
Diagnosis of acute exacerbation was confirmed if patients included all of 1,
2, and 3 plus at least either of 4 or 5 of the criteria.
Pneumonia was diagnosed by the presence of new and/or progressive
pulmonary infiltrates on chest radiography plus two or more of the follow-
ing criteria: fever (38C), leukocytosis (12 3 109/L), purulent sputum, or
isolation of pathogen in respiratory secretions.
Regarding acute respiratory distress syndrome (ARDS), we used the
American–European Consensus Conference Definition for acute respiratory
distress syndrome.6
Perioperative and Postoperative Management
Chest radiographs were routinely taken on the first and third postopera-
tive days and on the day after chest tube removal. Additional chest radio-
graphs were taken, depending on the patients’ clinical state, as opposed to
including all symptoms and signs. If infiltrates were revealed on chest
radiograph suggestive of ARDS or acute pulmonary embolism, high-resolu-
tion computed tomographic scan was performed for the differential diagno-
sis of these lung diseases.
Oxygen inhalation was administered at minimal level tomaintain oxygen
saturation at 92% or greater if patients did not have dyspnea or if they un-
derwent any change in cardiorespiratory conditions owing to mild hypoxia.
The steroid pulse therapy with methylpredonisolone (1 or 2 g per day for
3 or 4 days as one course) was used as the first line treatment for acute post-1358 The Journal of Thoracic and Cardiovascular Suoperative exacerbation of IPF. In this series, neither immunosuppressive
agent nor nitric oxide inhalation therapy was used.
Statistical Analysis
Statistical evaluation was performed by standard computer software
(SPSS 9.0; SPSS, Inc, Chicago, Ill). All data are presented as mean  stan-
dard deviation. Differences in continuous and categorical values were tested
by unpaired the Student t test and c2 square test (or Fisher’s exact test),
respectively. To account for the risk factor of morbidity or mortality after
pulmonary resection for lung cancer, we used the logistic regression analy-
sis. Furthermore, to account for the risk factor of late death after operation
for patients with PLC in combination with IPF, we used the Cox propor-
tional hazard model. Clinicopathologic related factors were quantified by
univariate analysis and then all factors with P<.10 in the univariate analysis
were included in the multivariate Cox hazard model together.
RESULTS
Acute postoperative exacerbation of IPF, ARDS, and the
need for prolonged mechanical ventilatory assist (>2 days)
for respiratory failure were more common in the patients
with IPF than in those without (Table 2). IPFwas a risk factor
for causing these postoperative respiratory complications.
Four (7.1%) of these 56 patients had acute postoperative
exacerbation of IPF, which occurred on about postoperative
day 5 (range day 3–7). Two patients recovered from the first
exacerbation with respiratory failure necessitating mechani-
cal ventilation, but the subsequent exacerbations developed
on the 24th and 27th postoperative days, accompanied by
more severe respiratory dysfunction. All patients died of
the exacerbation within 42 days after the operation. Bacterial
pneumonia developed in 3 of the 4 patients (Table E1).
The percentage of diffusion capacity of the lung for car-
bon monoxide showed no differences between patients
with the exacerbation and patients without it. No patient
who underwent wedge resection of the lung had an exacer-
bation after the operation. There were no differences in the
other values of pulmonary function, serologic data, opera-
tive factors, and histopathologic factors between the two
groups (Table 3).
Hospital death after pulmonary resection for lung cancer
was more common in patients with IPF than patients without
(7.1% vs 1.9%), and the odds ratio was 4.036 (P ¼ .016)
(Table 4).
Postoperative Pulmonary Function After Lower
Lobectomy
Postoperative pulmonary function in 4 to 6 months after
a lower lobectomy was compared between patients without
IPF (n ¼ 25) and patients with IPF (n ¼ 36). Although no
substantial differences were observed in postoperative vital
capacity (VC) and FEV1.0 between the two groups, percent-
ages of postoperative VC to preoperative VC (78.3% in pa-
tients without IPF vs 67.0% in patients with IPF; P ¼ .038)
and postoperative FEV1.0 to preoperative FEV1.0 (81.3% vs
67.7%; P ¼ .006) was significantly lower in patients with
IPF than in patients without IPF (Table E2).rgery c November 2008




In patients undergoing surgical treatment for pathologic
stage I PLC, actuarial survival curve and recurrence-free sur-
vival curvewere comparedbetween patientswith IPF (n¼ 28)
and patients without IPF (n¼ 526). Actuarial 5-year survival
was 83.0% and 61.6% in patients without IPF and patients
with IPF, respectively. Actuarial survival was significantly
worse in patients with IPF than in patients without IPF
(P ¼ .0189) (Figure 1).
Furthermore, actuarial 5-year recurrence-free survival
was 83.1% and 56.0% in patients with IPF and those with-
out, respectively. The actuarial recurrence-free survival was
TABLE 2. Risk of IPF associated with postoperative pulmonary
morbidity
c2 test Logistic regression analysis
IPF () IPF (þ) P value OR (95% CI) P value
Pneumonia 23 (2.8) 4 (7.1) .238 2.60 (0.87–7.817) .088
APEIP 0 (0.0) 4 (7.1) <.001 30.30 (5.40–166.67) <.001
ARDS 7 (0.9) 4 (7.1) .004 2.30 (2.48–31.25) .001




11 (1.4) 4 (7.1) .013 5.53 (1.70–17.86) .004
Pneumorrhea
(>7 d)
46 (5.7) 6 (10.7) .142 0.51 (0.21–1.24) 0.138
BPF 3 (0.4) 0 (0) 0.999 34.48 (0–120.90) 0.783
IPF, Idiopathic pulmonary fibrosis; OR, odds ratio; CI, confidence interval; APEIP,
acute postoperative exacerbation of interstitial pneumonia; ARDS, acute respiratory
distress syndrome; BPF, bronchopleural fistula.




(n ¼ 56) P value
Age (y) 65  9 68  7 .017
Male sex 517 (64.4%) 50 (89.3%) <.001
Histology ¼ Sq 196 (24.7%) 28 (50.0%) <.001
(Ad/Sq/others) 503/196/103 18/28/10





Lower lobe 275 (34.3%) 36 (64.3%) <.001
Right side 483 (60.2%) 32 (57.1%) .649
Pulmonary function
%VC (%) 106.0  18.1 103.8  19.0 .409
FEV1.0% (%) 75.7  12.2 75.0  9.6 0.696
%DLCO (%) 86.8  27.2* 61.4  19.2 <.001
P-stage I 526 (65.6%) 28 (50.0%) .0018
(II/III/IV/?) (90/140/13/33) (5/14/3/6)
IPF, Idiopathic pulmonary fibrosis; Sq, squamous cell carcinoma; Ad, adenocarci-
noma; WR, wedge resection; Seg, segmentectomy; Lob, lobectomy; Bilob, bilobec-
tomy; Pn, pneumonectomy; %VC, percentage of vital capacity; FEV1.0%,
percentage of forced expiratory volume in 1 second to forced vital capacity;
%DLCO, percentage of diffusing capacity of the lung for carbon monooxide; P-stage,
pathologic stage; *available data number was 150.The Journal of Thoracic and Casignificantly worse in patients with IPF than in patients with-
out IPF (P ¼ .0007) (Figure 2).
Regarding the other stages of PLC, actuarial 5-year sur-
vival was 72.4% in patients without IPF (n ¼ 90) and
40.0% in patients with IPF (n ¼ 5) (P ¼ .18) in pathologic
stage II PLC, 38.2% (n ¼ 140) versus 31.8% (n ¼ 14)
TABLE 3. Demographic data in patients with IPF in relation to the
acute exacerbation of IPF after operation
Exacerbation
() (n ¼ 52)
Exacerbation
(þ) (n ¼ 4) P value
Age (y) 68  7 69  6 .911
Male sex 47 3 .373
Brinkman index 937  648 543  618 .254
VC (L) 3.30  0.74 2.81  0.98 .219
%VC (%) 105.2  18.6 90.9  19.6 .149
FEV1.0 (L) 2.37  0.63 2.17  0.63 .534
FEV1.0% (%) 74.4  9.6 81.8  5.3 .134
DLCO (mL/min/mm
Hg/L)
13.9  4.2 10.3  2.2 .114
%DLCO (%) 62.2  19.2 45.5  10.4 .095
PaO2 (mm Hg) 80.9  8.4 83.8  8.1 .214
WBC (/mm3) 6829  1689 6100  1178 .648
CRP (mg/dL) 0.8  1.4 0.3  0.2 .472
LDH (IU/L) 289  114 394  85 .081
SP-D (ng/dL) 218  248 246  38 .827
KL-6 (U/mL) 712  460 721  272 .974
Operation time (min) 243  102 216  65 .605
Operative procedure
Wedge resection 9 0 1.000





Pathologic stage ¼ 1 27 1 .611
(I/II/II/IV/unknown) (27/4/12/3/6) (1/1/2/0)
Tumor location
Right 31 1 .303
Upperþmiddle 19 2 .626
Brinkman index, Cigarettes per day 3 years;%VC,% vital capacity; FEV1.0%, per-
centage of forced expiratory volume in 1 second to forced vital capacity; DLCO, dif-
fusing capacity of the lung for carbon monoxide;%DLCO, percent diffusing capacity
of the lung for carbon monoxide; PaO2, arterial oxygen tension;WBC,white blood cell
count; CRP, C-reactive protein; LDH, lactate dehydrogenase; SP-D, surfactant pro-
tein-D; KL-6, sialylated carbohydrate antigen KL-6; VATS, video-assisted thoraco-
scopic surgery; Ad, adenocarcinoma; Sq, squamous cell carcinoma.
TABLE 4. Risk of operative mortality in IPF
c2 test Logistic regression analysis
IPF () IPF (þ) P value OR (95% CI) P value
Hospital
death
15 (1.9%) 4 (7.1%) .030 4.04 (1.29–12.60) .016
30-day
mortality
7 (0.9%) 2 (3.6%) .112 4.20 (0.85–20.73) .078
90-day
mortality
26 (3.2%) 4 (7.1%) .126 2.30 (0.77–6.82) .135
IPF, Idiopathic pulmonary fibrosis; OR, odds ratio; CI, confidence interval.rdiovascular Surgery c Volume 136, Number 5 1359
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S(P¼ .08) in stage III PCL, and 15.4% (n¼ 13) versus 0.0%
(n ¼ 3) (P ¼ .02) in stage IV PLC. Furthermore, actuarial
recurrence-free survival was 62.0% in patients without
IPF and 54.2% in patients with IPF (P ¼ .004), 23.1% ver-
sus 20.2% (P¼ .34), and 37.3% versus 43.2% (P¼ .65) in
pathologic stage II, III, and IV PLC, respectively.
Limited resection for patients with PLC concomitant with
IPF has no effect on the late outcome after surgical treat-
ment. The 5-year survival of limited resection compared
with lobectomy, the survival of wedge resection, segmentec-
tomy, and lobectomy, were 62.4%, 50.0%, and 53.6 %,
respectively (P ¼ .93).
Sixteen of 52 patients in whom acute postoperative exac-
erbation of IPF did not develop immediately after operation
died of exacerbation of pulmonary fibrosis (PF) (n ¼ 5),
FIGURE 1. Actuarial cumulative survival curve in patients with patho-
logic stage I lung cancer. UIP, Usual interstitial pneumonia.
FIGURE 2. Actuarial cumulative disease-free survival curve in patients
with pathologic stage I lung cancer. UIP, Usual interstitial pneumonia.1360 The Journal of Thoracic and Cardiovascular Surecurrence of lung cancer (n ¼ 8), bacterial pneumonia
(n ¼ 2), and cerebral infarction (n ¼ 1) in late term after
lung resection. Table 5 shows the comparison between pa-
tients with late death and patients without. The frequencies
of cancer recurrence and late exacerbation of PF were
higher in patients with late death than in patients without.
Multivariate Cox proportional hazard model showed that
the significant predictors associated with late death were late
exacerbation of PF and the existence of tumor recurrence
(Table 6).
DISCUSSION
The median survival among patients with IPF from the
date of diagnosis is 2 to 4.2 years.7-9 The relative survival
of patients with IPF at 5 years compared with the expected
survival determined from census data is 63.7% (95% confi-
dence interval 53.8–73.6).7
There are reports that the incidence of lung cancer is in-
creased in patients with IPF and that this effect is indepen-
dent of the effect of cigarette smoking10 or mutations of
the p-53 gene.11 However, other studies did not show an in-
creased risk of lung cancer.12,13 Another possible mecha-
nism for the development of lung cancer is carcinogenesis
caused by PF through the promotion of atypical epithelial
proliferation.14 Mizushima and associates15 reported that
154 (3.12%) of 4931 patients with lung cancer from 1975
to 1977 in Japan were associated with IPF: 23 patients
with synchronous multiple lung cancer and 131 with single
lung cancer. In these 154 patients, most tumors were ob-
served in male patients, smokers, and in peripheral regions
of the lung. Occurrence in the lower lobes, where a fibrotic
shadow was prominent, was significantly more prevalent in
the IPF–lung cancer groups than for the whole lung cancer
group. The distribution of histologic types in the IPF–single
lung cancer group was similar to that of the whole lung
cancer group.
Operative mortality is considered to be higher in patients
with PF than in control patients (17% vs 3.1%; P<.01) and
there is a higher procedure-specific mortality in PF for pneu-
monectomy (33% vs 5.1%; P< .01) and lobectomy (12%
vs 2.6%; P< .01).16
In the recent study,4 the long-term survival of patients
who had lung cancer resection appears to be unaffected by
the association with interstitial lung disease. They described
that this reason could be explained by an adequate preoper-
ative selection based on pulmonary function tests and a pref-
erential choice for lobectomies. Thus, surgical resection
should be offered to properly selected patients with lung
cancer and underlying interstitial lung disease. Okamoto
and associates2 described that in patients with lung cancer
concomitant with IPF, the actuarial 2-year survival after pul-
monary resection was 52% overall, 58% for patients with
N0 or N1 disease and 25% for those with N2 disease; thergery c November 2008
Watanabe et al General Thoracic SurgeryTABLE 5. Univariate comparisons between patients with late death and patients without late death
Values Late death (þ) (n ¼ 16) Late death () (n ¼ 36) P value
Survival time (mo) 18  15 (4–64) 42  28 (12–102) .003
Age (y) 69  6 (59–77) 68  7 (53–79) .850
Male sex 15 32 .999
Brinkman index 814  515 (0–1600) 1006  713 (0–3000) .400
Histologic type
Ad 4 11 .752
Pathologic stage I
Tumor location
Right 9 22 .768
Lower 12 21 .353
Operation time (min) 229  142 (60–570) 229  142 (60–570) .999
Procedure
Wedge resection 5 4 .088
VATS 9 25 .367
VC (L) 3.06  0.78 (1.58–4.42) 3.40  0.70 (1.86–4.75) .177
%VC (%) 102.5  23.1 (50.5–144.4) 106.5  16.1 (72.6–131.3) .490
FEV1.0 (L) 2.27  0.71 (1.36–3.86) 2.42  0.60 (1.27–3.86) .490
%FEV1.0 (%) 74.2  8.5 (63.0–88.0) 74.5  10.3 (54.0–101.0) .923
DLCO (mL/min/mm Hg/L) 13.9  4.7 (7.4–22.1) 13.8  4.2 (6.7–23.9) .972
%DLCO (%) 61.4  20.7 (27.0–103.5) 62.6  19.0 (28.1–100.9) .863
PaO2 (mm Hg) 80.3  5.8 (72.8–88.6) 81.3  9.7 (68.6–97.6) .779
SP-D (ng/dL) 190  124 (87–396) 182  125 (36–523) .705
KL-6 (U/mL) 839  496 (438–1678) 677  458 (277–2263) .501
Late EPF 5 2 .023
Tumor recurrence 8 3 .002
Brinkman index, Cigarettes/day3 years; ad, adenocarcinoma; VC, vital capacity;%VC,% vital capacity; FEV1.0, forced expiratory volume in 1 second; FEV1.0%, percentage of
forced expiratory volume in 1 second to forced vital capacity; %DLCO, % diffusing capacity of the lung for carbon monoxide; SP-D, surfactant protein-D; KL-6, sialylated
carbohydrate antigen KL-6; VATS, video-assisted thoracoscopic surgery; EPF, exacerbation of pulmonary fibrosis.G
T
Slong-term results were poor partly because of the high inci-
dence of a second PLC and partly because of the poor natural
history of IPF. In our series, actuarial survival in patients
with pathologic N0 disease was 61.6%. Recurrence or sec-
ond development of the lung cancer is very common in these
patients; therefore, these patients require intensive surveil-
lance even after curative pulmonary resection for lung can-
cer. In addition, the postoperative mortality of lung
resection for lung cancer concomitant with IPF is very
high in comparison with that for simple lung cancer because
of acute exacerbation of IPF. The long-term outcomes are
poor because of the high incidence of second lung cancer
and because of the deterioration of IPF itself. However,
the poor results do not directly mean that surgical treatment
for lung cancer concomitant with IPF should be limited or
avoided, because the natural history of patients with lung
cancer concomitant with IPF has not been clarified yet. Of
course, we should exclude patients with lung cancer and
IPF from the criteria for pulmonary resection if the survival
is higher in patients without pulmonary resection than pa-
tients with, because the postoperative 5-year survival
(61.6%) for patients with stage I primary lung cancer con-
comitant with IPF was similar to the relative 5-year survival
(63.7%)7 of patients with IPF after the diagnosis from the
census data. A randomized controlled trial is necessary toThe Journal of Thoracic and Ccompare the survival after surgical treatment for lung cancer
with IPF versus nonsurgical treatment.
In this study, as described previously by Yoshimura and
associates,5 acute deterioration of interstitial lung disease
immediately after lung resection in these patients was
defined as acute postoperative exacerbation of IPF.
Few reports1,2,5 have been published on acute exacerba-
tion of IPF after lung resection for patients with PLC con-
comitant with IPF. Surprisingly, most of these were
reported from Japan. The clinical concept of acute exacerba-
tion of IPF has not been accepted in other countries because
of lack of studies on it. Okamoto and associates2 reported
that postoperative exacerbation was observed in 4 (20%)
of 20 patients who had IPF before surgery for PLC, and 3
of the 4 patients died. Furthermore, a higher incidence of
TABLE 6. Predictors of late death by multivariate Cox regression
analysis applied to patients with IPF
Variables HR (95% CI) P value
Wedge resection 0.74 (0.21–2.60) .635
Late EPF 9.62 (2.070–40.00) .002
Tumor recurrence 7.75 (1.789–33.33) .006
IPF, Idiopathic fibrosis; HR, hazard ratio; CI, confidence interval; EPF, exacerbation
of pulmonary fibrosis.ardiovascular Surgery c Volume 136, Number 5 1361
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Sidiopathic pulmonary exacerbation of IPF was observed in
patients who had undergone lobectomy and pneumonec-
tomy. Koizumi and associates1 reported that exertional
dyspnea (Hugh–Jones classification) greater than grade II,
serum C-reactive protein greater than 2.0 mg/dL, serum lac-
tate dehydrogenase greater than 400 IU/L, and percentage of
total lung capacity less than 95% were considered to be pre-
operative risk factors of acute exacerbation and that methods
to approach the thorax, such as posterolateral thoracotomy,
muscle-sparing thoracotomy, and video-assisted thoracic
surgry, did not pose an effect on the development of exacer-
bation of IPF. Kushibe and associates17 also reported that
patients with IPF who had postoperative acute lung injury/
ARDS had a significantly lower preoperative percent forced
VC than those without such complications. Our results
showed that no clinical factors were implicated on acute
exacerbation. Even serum C-reactive protein or lactate
dehydrogenase did not relate to the development of the
exacerbation. That is why the patients with active phase
IPF were excluded from our inclusion criteria for surgical
resection.
Low oxygen inhalation, use of steroids,18 limited sur-
gery,2 avoidance of hyperinflation of the lung during opera-
tion, and prevention of postoperative pneumonia by the use
of prophylactic antibiotic therapy have been used to prevent
acute exacerbation of IPF after lung resection. However,
none of these therapies presents any definitive evidence
that one could prevent the development of the postoperative
exacerbation of IPF. At the cellular level, IPF/UIP may in
part be an oxidant-mediated disease,19 and oxygen therapy
might be expected to increase tissue concentrations of toxic
oxygen radicals.20
Alveolar fluid is severely depleted in bronchoalveolar
fluid from patients with IPF/UIP, and antioxidant therapy
with N-acetylcysteine has been reported to improve the con-
centration of glutathione in the bronchoalveolar fluid of pa-
tients with IPF/UIP.21 Recent study revealed the following
findings: (1) Lung re-expansion after one-lung ventilation
(OLV) provoked severe oxidative stress. (2) The degree of
generated oxygen-derived free radicals was associated
with the duration of OLV. (3) Patients with lung cancer
had a higher production of oxygen-derived free radicals
than the normal population. (4) Tumor resection removes
a large oxidative burden from the organism. (5) Mechanical
ventilation and surgical trauma are weak free radical gener-
ators. (6) Manipulated lung tissue is also a source of
oxygen-derived free radicals, not only intraoperatively but
also for several hours later.22 These results indicate that
shortening OLV duration and avoiding manipulation of
lung tissue may inhibit the occurrence of the acute postop-
erative exacerbation of IPF resulting from oxygen-derived
free radicals. However, it is very hard to strike a balance be-
tween shortening OLV duration and avoiding the manipula-
tion clinically.1362 The Journal of Thoracic and Cardiovascular SuOnly steroid pulse therapy has been considered for the
treatment of acute postoperative exacerbation of IPF, but
we were able to save none of 4 patients who had the exacer-
bation of IPF. Although there are some reports that second
line therapies, such as immunosuppressant23,24 and nitric
oxide therapy,25 prolonged survival, further study on these
therapies is required.
There have been no reports on pulmonary function after
lung resection for lung cancer in patients with IPF. Our
data show that patients with IPF lost more VC and FEV1.0
after lower lobectomy than patients without. They have pro-
ceeded with daily life at a lower pulmonary function than the
postoperative predictive value. In patients with lung cancer
concomitant with IPF, it is very important to estimate post-
operative lung function, but it is very difficult to do so for
lack of a predictive formula. We must emphasize that the
conventional formula of each postoperative predictive VC
or FEV1.0 overestimates the true postoperative values even
after lower lobectomy, which relatively preserves postoper-
ative pulmonary function because residual upper lobe injury
resulting from IPF is lesser than in the lower lobe injury.
Strategy for Recurrence or Second Development
of Lung Cancer
In patients with PLC and IPF, it was very difficult to un-
dergo reresection because their pulmonary function is lower
than at the first operation. In our series, only 1 patient under-
went reresection of the lung. On one hand, chemotherapy
and/or radiotherapy26 could possibly contribute to the devel-
opment of PF. It is considered that single administration of
platina agents, such as cisplatin and carboplatin, hardly in-
duce pulmonary injury27; however, vindesine and etopo-
side,28 which are usually used together with cisplatin, or
a single administration of any of them induces fatal pulmo-
nary injury. When using these agents, one should take
extremely good care of the patients with IPF.
Limitations of this Study
A number of limitations are inherent in a retrospective sin-
gle institution study. A retrospective analysis is susceptible
to various sources of bias that may not have been identified
and controlled. At occurrence of the acute exacerbation of
IPF after lung resection for lung cancer concomitant with
IPF, adjuvant therapy added to steroid pulse therapy is not
determined, and at the lung cancer recurrence after lung re-
section, we do not have definitive strategy. Only 4 patients
underwent acute exacerbation of IPF, in which the case num-
ber might have been too little to predict some risk factor for
the development of the exacerbation.
Another limitation of the present study is the long time pe-
riod of the analysis (about 11 years) wherein the surgical
techniques (video-assisted thoracic surgery is predominant
in late term of study period) and perioperative management
differ. After 1999, we routinely administrated erythromycinrgery c November 2008
Watanabe et al General Thoracic Surgery(300 mg per day) or clarythromycin (400 mg per day) for pa-
tients with lung cancer who had complications with IPF, in
which the administration period was between 1 week preop-
eratively and 3 or 4 weeks postoperatively.
A further limitationmay be the definition of acute postoper-
ative exacerbation of IPF. We could not distinguished acute
postoperative exacerbation of IPF from acute interstitial pneu-
monia.Wecannot deny that there could be twodiseases occur-
ring together or as a single disease entity in this study.
CONCLUSIONS
Our retrospective data reveal the following implications:
(1) Acute postoperative exacerbation of IPF causes high
mortality. (2) It is very difficult to predict the occurrence
of the postoperative exacerbation of IPF. (3) Although the
long-term results of surgical treatment for lung cancer con-
comitant with IPF are worse than that without IPF, the sur-
gical treatment of the PLC is effective in patients with
stage I lung cancer with concomitant IPF.
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STABLE E1. Summary of patients who had postoperative acute exacerbation of IPF
Case, sex, age (y) Procedure P-stage Onset (POD) SPT (No. of times) Concomitant disease SP-D/LDH ([IU/L]/[ng/dL]) POS
1, M, 68 LLL 1B 7, 27 2 BPn (Klebsiela) 1099/1120 42
2, M, 61 LUL 3B 5 2 BPn (MRSA, PA) 850/1112 13
3, F, 74 RUL 3B 3, 24 3 Bpn (MSSA, PA) 1342/1842 32
4, M, 72 LLL 2B 6 1 — NA /1206 9
IPF, Idiopathic pulmonary fibrosis; P-stage, pathologic stage; POD, postoperative day; SPT, steroid pulse therapy for exacerbation of IPF; SP-D, surfactant protein-D; LDH, lactate
dehydrogenase; POS, postoperative survival; M, male; F, female; LLL, left lower lobectomy; LUL, left upper lobectomy; RUL, right upper lobectomy; Bpn, bacterial pneumonia;
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PA, Pseudomonas aeruginosa, NA, not available.1363.e1 The Journal of Thoracic and Cardiovascular Surgery c November 2008
Watanabe et al General Thoracic SurgeryTABLE E2. Pulmonary function in lower lobectomy cases
Variables IPF () (n ¼ 250) IPF (þ) (n ¼ 36) P value
Preop VC (L) 3.22  0.79 3.29  0.71 .710
Postop VC (L) 2.55  0.77 2.25  0.64 .270
Preop FEV1.0 (L) 2.39  0.68 2.35  0.57 .800
Postop FEV1.0 (L) 1.99  0.61 1.67  0.42 .122
Postop VC/preop VC (%) 78.3  15.1 67.0  12.1 .038
Postop FEV1.0/preop FEV1.0 (%) 81.3  13.5 67.7  10.6 .006
Preop, Preoperative; Postop, postoperative; VC, vital capacity; FEV1.0, forced expiratory volume in 1 second.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 5 1363.e2
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